Scientists at the University of Adelaide have created a novel delivery system using “smart” nanoparticles to administer mRNA therapy directly into tumors, potentially overcoming one of the most persistent barriers in cancer immunotherapy. The findings, published in Science Advances, demonstrate that this targeted approach can reprogram immune cells that cancers typically co-opt to suppress the body’s natural defenses.
Tumors often create a hostile microenvironment that neutralizes immune cells or even reprograms them to protect the malignancy. Chunxia Zhao, a professor at the University of Adelaide, noted that while the immune system is capable of attacking cancer, the tumor environment frequently inhibits these cells from performing their duties. The new study addresses this by focusing on tumor-associated macrophages, which, when influenced by cancer signals, block the arrival and effectiveness of T cells—the immune system’s primary weaponry against tumors.
The research team engineered nanoparticles coated with antibodies that specifically bind to TREM2, a protein found on the surface of these immunosuppressive macrophages. This targeting mechanism ensures the therapy reaches only the intended cells within the chaotic tumor environment. Inside the nanoparticles, the mRNA carries instructions for producing CXCL9, a chemical signal that recruits T cells to the site of the cancer. The particles also delivered resiquimod, a drug that stimulates additional immune pathways.
In laboratory tests, the treatment successfully shifted macrophages from a lethargic, tumor-supporting state to an active immune state. Markers of immune activity, such as NOS2, increased by nearly 90-fold, while signs of immunosuppression significantly decreased. When administered to mice with aggressive breast cancer, three doses of the smart nanoparticles resulted in slowed tumor growth. CXCL9 concentrations in the treatment group were approximately four times higher than in controls, and the proportion of immunosuppressive macrophages dropped by 63 percent.
The researchers also tested the therapy in combination with existing immune checkpoint inhibitors. While the combination did not further shrink tumors, it induced significant immune changes, including increased populations of different T cell types in the tumors and nearby lymph nodes—changes associated with the potential for long-lasting immune memory against the cancer.
This development builds on rapid advancements in mRNA technology since its public introduction through COVID-19 vaccines. However, delivering immune-activating signals systemically carries the risk of dangerous side effects from overstimulating the entire immune system. By restricting the therapy to tumor-specific macrophages, the “smart” nanoparticle approach minimizes these risks while maximizing localized anti-cancer activity.
So, it basically wakes up the sleepy immune cells and calls in the cavalry. Simple concept, but likely complex engineering.
The 90-fold increase in NOS2 markers is remarkable. It shows how potent localized reprogramming can be compared to systemic therapies.
I’m skeptical about mouse models translating to human trials. How long until we see actual clinical results for breast cancer patients?
This is a game-changer. Targeting macrophages directly instead of flooding the whole body with immune stimulants is brilliant.